| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6229002 Complex of nucleic acid which binds to platelet derived growth factor and nonimmunogenic, high molecular weight compound; for targeted diagnostic and therapy; anticarcinogenic agents; cardiovascular disorders; kidney disease |
| 05/08/2001 | US6228889 Methods for treatment of conditions associated with lactosylceramide |
| 05/08/2001 | US6228861 Benign prostatic hyperplasia; anticholesterol agents; impotency; intraocular pressure; antiarrhythmia agents |
| 05/08/2001 | US6228853 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228584 Nucleotide sequences for use in the detection of streptococcus |
| 05/08/2001 | US6228394 Supercritical fluid extraction of mould lubricant from hard shell capsules |
| 05/08/2001 | US6228360 Immunoglobulins binding to human von willebrand factor with chains |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2170289C A method of treating liver disease and like indications with vasodilating agents |
| 05/08/2001 | CA2167040C New alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 05/08/2001 | CA2027530C W-phenoxy-heterocyclic compounds |
| 05/03/2001 | WO2001031048A1 Nitric oxide donor composition using red rice fermented with monascus and a pharmaceutical composition containing the same |
| 05/03/2001 | WO2001031036A2 Modified viral surface proteins which bind to cells of tumor vasculature |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031008A2 Human and rat fgf-20 genes and gene expression products |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030969A2 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | WO2001030848A2 Nucleic acids of the human abc1 gene and applications thereof |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030780A2 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030768A1 Methods and compositions utilizing quinazolinones |
| 05/03/2001 | WO2001030767A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030758A1 Drugs for the treatment of malignant tumours |
| 05/03/2001 | WO2001030756A1 Benzamidine derivatives |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030750A1 Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof |
| 05/03/2001 | WO2001030745A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase |
| 05/03/2001 | WO2001030389A1 Wound contraction inhibitors |
| 05/03/2001 | WO2001030387A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | WO2001030357A1 Hormonal composition based on a progesterone and an oestrogen and use thereof |
| 05/03/2001 | WO2001030356A1 Hormonal composition based on a progestational agent and an oestrogen and use thereof |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030347A1 Treatment or prevention of hypotension and shock |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030333A2 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | WO2001030330A2 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | WO2001030328A2 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | WO2001030327A2 Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of ischaemic conditions |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | WO2001030137A1 N-calcium channel knockout animal |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951702A1 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-amino-3,4-dihydro-quinazolines for the preparation of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951701A1 Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-imidazolyl-substituted carbinols of manufacturing a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951671A1 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist and its use as an endothelin antagonist |
| 05/03/2001 | DE19951418A1 Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid Process for the preparation of N- (4,5-Bismethansulfonyl-2-methyl-benzoyl) guanidine, hydrochloride |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389034A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2389012A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | CA2388965A1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | CA2388956A1 Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of ischaemic conditions |
| 05/03/2001 | CA2388950A1 Nucleic acids of the human abc1 gene and their therapeutic and diagnostic application |
| 05/03/2001 | CA2388934A1 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | CA2388637A1 Human fgf-20 gene and gene expression products |
| 05/03/2001 | CA2388617A1 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388479A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2387857A1 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | CA2387685A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | CA2387506A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | CA2387378A1 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | CA2386750A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | CA2386441A1 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/02/2001 | EP1096016A1 Platelet-activating factor acetylhydrolase |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095933A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095654A2 Use of raloxifene and its analogs for the manufacture of a medicament for the Inhibition of LDL oxidation and atherosclerosis |
| 05/02/2001 | EP1095651A2 Multipor food protection |
| 05/02/2001 | EP1095274A1 Trifunctional reagent for conjugation to a biomolecule |
| 05/02/2001 | EP1095154A2 Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) |
| 05/02/2001 | EP1095139A2 Secreted proteins |
| 05/02/2001 | EP1095132A1 Methods for implanting cells |
| 05/02/2001 | EP1095057A1 Matrix metalloproteinase inhibitors containing aminomalonic acid derivatives and peptide backbone modified derivatives thereof |
| 05/02/2001 | EP1095044A1 Piperazynil pyrimidine dione compounds selective for adrenoceptors |
| 05/02/2001 | EP1095039A2 New pharmaceutically active compounds |
| 05/02/2001 | EP1095021A1 Quinoline derivatives |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |